drugset / Trial / NCT01987232
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer
SequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for patients with extensive-stage small-cell lung cancer (ES SCLC).
Timeline
- Start
- 2013-11-05
- Primary completion
- 2016-08
- Completion
- 2017-05-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Carfilzomib | Other / unclassified | — | Intravenous |
| Subject | Etoposide | Small molecule | 100 mg/m2 | Intravenous |